Lipocine Inc. (LPCN)

Market Cap	25.19M
Revenue (ttm)	7.92M
Net Income (ttm)	-4.06M
Shares Out	5.35M
EPS (ttm)	-0.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,682
Open	4.730
Previous Close	4.760
Day's Range	4.638 - 4.855
52-Week Range	2.380 - 11.790
Beta	1.19
Analysts	Strong Buy
Price Target	10.00 (+112.31%)
Earnings Date	Nov 7, 2024

About LPCN

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company’s pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: LPCN
• Website: https://www.lipocine.com

Analyst Forecast

According to one analyst, the rating for LPCN stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target

$10.0

(112.31% upside)

Analyst Consensus: Strong Buy